ArticleWorld journal of gastroenterology2015
Expression of COX-2 and HER-2 in colorectal cancer and their correlation.
Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis.Oncotarget · 2017Pooled it
- COX-2/C-MET/KRAS status-based prognostic nomogram for colorectal cancer: A multicenter cohort study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationTrial
- The Impact of Aspirin Use on In-Hospital Outcomes and Metastatic Disease in Colorectal Cancer: An Evaluation of the National Inpatient Sample.Journal of clinical medicine · 2026Article
- Reprogramming inflammation: Mechanisms and therapeutic targeting of eicosanoids and pro-resolving mediators.European journal of pharmacology · 2025Review
- Association of COX-2 Selectivity in Pain Medication Use with Endometriosis Incidence: Retrospective Cohort Study.Yonsei medical journal · 2025Article
- Study the Impact of NADPH oxidase1,TNF-alpha and Cyclooxygenase-2 On Colon Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Expression of cyclooxygenase-2 (COX-2) in colorectal adenoma in an indigenous African population in northern Nigeria.African journal of laboratory medicine · 2025Article
- Morphological Changes and Inflammation Preceded the Pathogenesis of 1,2-Dimethylhydrazine-Induced Colorectal Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Targeting inflammation as cancer therapy.Journal of hematology & oncology · 2024Review
- The relationship between nonsteroidal anti-inflammatory drugs and cancer incidence: An umbrella review.Heliyon · 2024Review
- Expression of cyclooxygenase-2 (COX-2) in colorectal carcinoma in an indigenous African population of Kano, Nigeria.Ecancermedicalscience · 2024Article
- Low prostaglandin-endoperoxide synthase-2 gene expression in colorectal carcinomas may predict poorer survival.Ecancermedicalscience · 2024Article
- Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies.Cancer management and research · 2024Review
- HER-2 Expression in Colorectal Cancer and Its Correlation with Immune Cell Infiltration.Biomedicines · 2023Article
- Trinity of inflammation, innate immune cells and cross-talk of signalling pathways in tumour microenvironment.Frontiers in pharmacology · 2023Review
- The Role of Inflammation-Associated Factors in Head and Neck Squamous Cell Carcinoma.Journal of inflammation research · 2023Review
- Ononitol Monohydrate-A Glycoside Potentially Inhibit HT-115 Human Colorectal Cancer Cell Proliferation through COX-2/PGE-2 Inflammatory Axis Regulations.International journal of molecular sciences · 2022Article
- Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress.Stem cell research & therapy · 2022Review
- NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase.International journal of molecular sciences · 2022Review
- The Role and Interactions of Programmed Cell Death 4 and its Regulation by microRNA in Transformed Cells of the Gastrointestinal Tract.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo detect the expression of COX-2 and HER-2 in colorectal cancer and to analyze their correlation and clinical significance.
methodsA total of 1026 colorectal cancer surgical specimens were collected from patients treated from December 2002 to December 2007 at the First Affiliated Hospital of Anhui Medical University. All specimens were made into 4-μm slices. The expression of COX-2 and HER-2 were detected by immunohistochemistry using the streptavidin-biotin-peroxidase method. The correlations between COX-2 and HER-2 expression and colorectal cancer clinical features were analyzed.
resultsThe positive rates of COX-2 and HER-2 expression in colorectal cancer were 77.97% (800/1026) and 46.20% (474/1026), respectively. There was a significant correlation between COX-2 and HER-2 expression in colorectal cancer (P < 0.05). In patients with tumor size ≥ 5 cm, the positive rates of COX-2 and HER-2 expression were 81.48% (308/378) and 57.94% (219/378), respectively. In patients with serosal invasion, the positive COX-2 and HER-2 expression rates were 80.53% (612/760) and 49.21% (374/760), respectively. In patients with lymph node metastasis, the positive expression rates were 85.04% (506/595) and 54.62% (325/595), respectively, and the positive expression rates differed significantly between patients with lymph node metastasis and those without (P < 0.05). In patients with Duke's C and D colorectal cancer, the positive COX-2 and HER-2 expression rates were 82.80% (443/535) and 57.94% (310/535), respectively. In patients with poorly differentiated colorectal cancer, the positive expression rates were 74.49% (210/282) and 52.84% (149/282), respectively (P < 0.05). In patients with distant metastasis, the positive expression rates were 82.27% (116/141) and 53.90% (76/141), respectively (P < 0.05). These findings suggest that COX-2 and HER-2 have synergistic effects in colorectal cancer. COX-2 and HER-2 expression had no significant correlation with sex, age, or tumor location.
conclusionCOX-2 and HER-2 are important markers for invasion and metastasis of colorectal cancer, and they act together to regulate the invasion and metastasis of colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.